An observational study in Advanced Neuroendocrine Carcinoma, sponsored by Hospices Civils de Lyon. Not yet recruiting at 1 site in France. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Hospices Civils de Lyon · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 60 studies in Neuroendocrine Tumors with a site in France — 19 open to participants now, 26 under way, 8 of them phase 3. Neuroendocrine Tumors · France.
Among the 60 studies in Neuroendocrine Tumors with a site in France, this one is the 8th largest by planned enrollment of the 20 observational ones that give a count, is one of 2 that started in 2026, is one of 20 observational ones, reaches primary completion later than 9 of the 25 other live ones, and was the 60th registered.
543 studies on the registry are indexed under Neuroendocrine Tumors; 135 are open to participants now.
Browse Neuroendocrine Tumors studies →19 of the 60 studies in Neuroendocrine Tumors with a site in France are open now. Recruiting first, the newest first:
Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz · Sites in France, United States, Brazil and 6 more countries
Ages 18+
Nantes University Hospital · Sites in France
Ages 18+
ITM Solucin GmbH · Sites in France, United States, Spain
Ages 24 mo–18 yrs
Exelixis · Sites in France, United States, Australia and 15 more countries
Ages 18+
Grupo Espanol de Tumores Neuroendocrinos · Sites in France, Spain
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 112 Neuroendocrine Tumors studies recruiting now, 73 (65%) set no upper age limit and 17 (15%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
60 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 18 · Phase 3 11 · Phase 4 3
First in 1997; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is above the median of 130 across 129 observational studies indexed under Neuroendocrine Tumors.
Median enrollment 129 across the 40 interventional studies, 118 across the 20 observational. Of the 30 that completed or were terminated, 15 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 60 have an industry lead sponsor. The 10 most frequent:
Hospices Civils de Lyon is the lead sponsor of 1,868 studies on the registry; 448 are open to participants now.
Hospices Civils de Lyon has 5 studies filed under Neuroendocrine Tumors — fewer than ten, so there is no comparison to draw.
11 of the studies in Neuroendocrine Tumors with a site in France that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05477576Phase 3RayzeBio, Inc.Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy | 2026-12 |
| NCT04919226Phase 3ITM Solucin GmbHLutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE | 2027-06 |
| NCT07087054Phase 3Crinetics Pharmaceuticals Inc.Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen | 2027-08 |
| NCT06881992Phase 3RezoluteA Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism | 2027-09 |
| NCT06430021Centre Hospitalier Universitaire DijonStudy of the Value of hPG80 (Circulating Progastrin) for the Diagnosis of Neuroendocrine Tumours in Patients With an MEN1 Mutation | 2026-12 |
Add all 11 to your calendar (.ics) → With an account.
Among the 60 studies in Neuroendocrine Tumors with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Neuroendocrine tumors are rare tumors with prolonged survival. The management of patients at advanced stage is centered on both locoregional control and systemic therapy. Systemic approaches include somatostatin analogs (SSA) that improve symptom control and slow tumor progression, peptide receptor radionuclide therapy (PRRT), targeted agents (everolimus, sunitinib and cabozantinib) and chemotherapy. All these therapies have demonstrated clinical benefit across multiple randomized and non-randomized studies, yet no high-level evidence defines the optimal sequence in which they should be administered in real-world metastatic settings.
The recent approval of cabozantinib, a multikinase inhibitor targeting VEGFR, MET, and AXL, represents a major advancement in the systemic management of NETs.
The retrospective study "CARE-NET", is a multicenter study which has the aims to describe the real-world use of cabozantinib (between January 2020 and August 2026) in France.
The study aims to enroll approximately 150 patients which initiate cabozantinib between January 2020 and August 2026 across participating centers.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adults ≥18 years. Histologically confirmed, well-differentiated NET (G1-G3) or typical/atypical thoracic carcinoids Metastatic or unresectable disease. Cabozantinib initiated between January 2020 and August 2026
To evaluate, in real-world clinical practice, the Disease Control Rate (DCR) achieved with cabozantinib among patients with advanced or metastatic well-differentiated NETs treated between January 2020 and August 2026.
This primary objective will be evaluated in the intention-to-treat population and in the "evaluable population" defined that patient who received at least one month of treatment (time between first and last dose of cabozantinib) and with an available imaging at least 2 months after the beginning of cabozantinib in order to assess the morphological change according to RECIST criteria 1.1.
Time frame: Retrospective data between January 2020 and August 2026
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Dec 2026; primary completion for Jan 2027, 1 month later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.